Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis.
Katschke KJ Jr, Helmy KY, Steffek M, Xi H, Yin J, Lee WP, Gribling P, Barck KH, Carano RA, Taylor RE, Rangell L, Diehl L, Hass PE, Wiesmann C, van Lookeren Campagne M. Katschke KJ Jr, et al. Among authors: barck kh. J Exp Med. 2007 Jun 11;204(6):1319-25. doi: 10.1084/jem.20070432. Epub 2007 Jun 4. J Exp Med. 2007. PMID: 17548523 Free PMC article.
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L. Singh M, et al. Among authors: barck kh. J Pathol. 2012 Aug;227(4):417-30. doi: 10.1002/path.4053. Epub 2012 Jun 28. J Pathol. 2012. PMID: 22611036
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS. Salphati L, et al. Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19. Clin Cancer Res. 2012. PMID: 22992516
Development and preclinical characterization of a humanized antibody targeting CXCL12.
Zhong C, Wang J, Li B, Xiang H, Ultsch M, Coons M, Wong T, Chiang NY, Clark S, Clark R, Quintana L, Gribling P, Suto E, Barck K, Corpuz R, Yao J, Takkar R, Lee WP, Damico-Beyer LA, Carano RD, Adams C, Kelley RF, Wang W, Ferrara N. Zhong C, et al. Clin Cancer Res. 2013 Aug 15;19(16):4433-45. doi: 10.1158/1078-0432.CCR-13-0943. Epub 2013 Jun 28. Clin Cancer Res. 2013. PMID: 23812669
30 results